Invention Grant
- Patent Title: CD123 binding agents and uses thereof
-
Application No.: US14844194Application Date: 2015-09-03
-
Publication No.: US09850310B2Publication Date: 2017-12-26
- Inventor: Francois Gaudet , Jennifer F. Nemeth , Ricardo Attar , Benjamin C. Harman , Yingzhe Li , Jinquan Luo , Ronan McDaid , Steven C. Pomerantz , Susan H. Tam , Alexey Teplyakov , John Wheeler , Sheng-Jiun Wu
- Applicant: Janssen Pharmaceutica NV
- Applicant Address: BE Beerse
- Assignee: Janssen Pharmaceutica NV
- Current Assignee: Janssen Pharmaceutica NV
- Current Assignee Address: BE Beerse
- Main IPC: C07K16/28
- IPC: C07K16/28 ; C07K16/30 ; C07K16/00 ; A61K39/395 ; A61K39/00

Abstract:
Provided herein are antibodies that immunospecifically bind to CD123. Also described are related polynucleotides capable of encoding the provided CD123-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor CD123-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with CD123-expressing cancer and thus may be amenable to treatment with a CD123-specific anti-cancer therapeutic, such as the multispecific antibodies against CD123 and CD3 described herein.
Public/Granted literature
- US20160068605A1 CD123 Binding Agents and Uses Thereof Public/Granted day:2016-03-10
Information query